MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Biphasic or Mixed

Combination of epithilioid and sarcomatoid mesothelioma types. Approximately 20-35% of cases are classified as mixed or biphasic mesothelioma.

Aquaporin-1 (AQP-1) expression in fluoro-edenite-induced mesothelioma effusions: an approach by cell-block procedure

Cytopathology 2018 June 6 [Link] Angelico G, Ieni A, Caltabiano R, Zeppa P, Tuccari G Abstract OBJECTIVE: Aquaporin 1 (AQP-1) is a water channel protein found in cell membranes, whose expression has been considered an independent favourable prognostic factor in pleural Malignant Mesothelioma (MM). The aim of this study is to evaluate the expression of […]

Comments Off on Aquaporin-1 (AQP-1) expression in fluoro-edenite-induced mesothelioma effusions: an approach by cell-block procedure

Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography?

Journal of Computer Assisted Tomography 2018 April 2 [Epub ahead of print] [Link] Escalon JG, Harrington KA, Plodkowski AJ, Zheng J, Capanu M, Zauderer MG, Rusch VW, Ginsberg MS Abstract OBJECTIVES: Determine imaging characteristics specific to epithelioid (eMPM), sarcomatoid (sMPM), and biphasic (bMPM) subtypes of malignant pleural mesothelioma (MPM) on computed tomography. METHODS: Preoperative computed […]

Comments Off on Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography?

National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study

The Annals of Thoracic Surgery 2017 December [Epub ahead of print] [Link] Saddoughi SA, Abdelsattar ZM, Blackmon SH Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) remains an aggressive malignancy that is difficult to cure. However, the treatment paradigm of MPM has evolved, and the national practice patterns are unknown. This study examined the national trends in […]

Comments Off on National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study

Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10-year experience

Comments Off on Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10-year experience

Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma

Oncoimmunology 2017 July [Link] Terra SBSP, Mansfield AS, Dong H, Peikert T, Roden AC Abstract Background: Programmed Cell Death 1-Ligand 1 (PD-L1) and Programmed Death Protein 1 (PD-1) blocking antibodies are promising immunotherapies for malignancies. We have previously shown PD-L1 expression in 40% of malignant mesothelioma (MM); however, the temporal and spatial heterogeneity of its […]

Comments Off on Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma

PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma

Asia-Pacific Journal of Clinical Oncology 2017 November [Epub ahead of print] [Link] Nguyen BH, Montgomery R, Fadia M, Wang J, Ali S Abstract AIM: There is currently a need to identify prognostic biomarkers to assist in a risk adopted approach in treatment of malignant pleural mesothelioma (MPM). Expression of programmed death ligand 1 (PD-L1) has […]

Comments Off on PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma

Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application

Chinese Journal of Pathology 2017 October [Link] Guo ZY, Sun WY, Michele Y, Zhang JL, Hu D, Su HN, Yang WM, Mao W Abstract Objective: To investigate the expression of BRCA-associated protein 1 (BAP1) in malignant mesothelioma, non-small cell lung cancer and carcinosarcoma, and its application in the differential diagnosis. Methods: Twenty-two cases of malignant […]

Comments Off on Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application

Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma

Comments Off on Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

Journal of Clinical Oncology 2017 September 11 [Epub ahead of print] [Link] Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, John T, Leighl NB, Reck M, Taylor P, Planchard D, Sørensen JB, Socinski MA, von Wangenheim U, Loembé AB, Barrueco J, Morsli N, Scagliotti G Abstract Purpose LUME-Meso is a phase […]

Comments Off on Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

JQ1, a BET inhibitor, synergizes with cisplatin and induces apoptosis in highly chemoresistant malignant pleural mesothelioma cells

Current Cancer Drug Targets 2017 June 23 [Epub ahead of print] [Link] Zanellato I, Colangelo D, Osella D Abstract Malignant pleural mesothelioma (MPM) is an asbestos-associated tumor with poor prognosis and few therapeutic options. JQ1, a selective antagonist of BRD4, modulates transcription of oncogenes, including MPM chemoresistance-associated c-Myc and Fra-1. We investigated if JQ1 could […]

Comments Off on JQ1, a BET inhibitor, synergizes with cisplatin and induces apoptosis in highly chemoresistant malignant pleural mesothelioma cells